Search Articles:

Vedolizumab in IBD. Crohn's disease, clinical response and remission were achieved in 54% (95% confidence interval (CI) 41-66%) and 22% (95% CI 13-35%) by week 6 and in 49% (95%CI 37-51%) and 32% (95%CI 23-42%) by week 14. Ulcerative colitis, clinical response and remission was achieved in 43% (CI 95% 37-49) and 25% (CI 95% 12-45) by week 6 and in 51% (95%CI 43-61%)and 30% (95%CI 24-36%) by week 14/22; at week 52, clinical response and remission. See Post

---